Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study.

"We will evaluate in all patients pre-treatment data :~* Melanoma staging at treatment initiation~* Melanoma characteristics at initial diagnosis~* Number and location of metastasis~* Performans status~* Demographic information"

"We will evaluate in all patients during study treatment :~* Rate of adverse events~* Type of adverse events~* Radiological response to treatment by CTscans that are routinely performed every three months."